However, in our present study of lung cancer, a relatively high immunoreactivity status of 17βHSD1 tended to be positively associated with ERβ (p=0.097), aromatase (p=0.057) and tumor stage (p=0.055) (Table 2), although that of 17βHSD2 was not associated with either ERβ (p=0.257) and/or aromatase status (p=0.309) (Table 2). This evidence concerns the gene CYP19A1 and lung carcinoma.